Imara Broadens Hematology Horizons With $63m Fundraising
Executive Summary
Imara has raised $63m to pursue its PDE9 inhibitor for sickle cell disease, and hopes to broaden the Phase II drug candidate into related blood disorders such as beta thalassemia.
You may also be interested in...
Enliven Takes Precision Oncology Ambitions Public In Merger With Imara
The planned all-stock transaction will enable Enliven to take over Imara’s Nasdaq listing with cash runway into 2026. Imara shareholders get contingent value rights tied to sold-off top candidate tovinontrine.
Finance Watch: Revolution Medicines Continues 2020’s Post-IPO Trend
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.
Finance Watch: Two New IPOs – IGM In the US, Henlius In Hong Kong – Gross Nearly $600m
Public Company Edition: IGM raised $175m to advance its IgM antibodies and Henlius brought in $410m for its novel drug and biosimilar platforms. Also, Acadia follow-on brings in $250m, PTC sells $350m worth of stock and debt, and Karyopharm royalty deal totals $150m.